{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:24:53Z","timestamp":1791563093465,"version":"4.3.4"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T00:00:00Z","timestamp":1710547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T00:00:00Z","timestamp":1710547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-024-10397-8","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T06:02:11Z","timestamp":1710568931000},"page":"785-797","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Budget impact analyses for treatment of heart failure. A systematic review"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9168-7546","authenticated-orcid":false,"given":"Abedin","family":"Teimourizad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdosaleh","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firooz","family":"Esmaeilzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,16]]},"reference":[{"issue":"1","key":"10397_CR1","first-page":"4","volume":"24","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA et al (2021) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 24(1):4\u2013131","journal-title":"Eur J Heart Fail"},{"key":"10397_CR2","unstructured":"National Collaborating Centre for Chronic Conditions (Great Britain) (2003)\u00a0Chronic Heart Failure: national clinical guideline for diagnosis and management in primary and secondary care. Royal College Phys"},{"issue":"6","key":"10397_CR3","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1002\/ehf2.13124","volume":"7","author":"D Tomasoni","year":"2020","unstructured":"Tomasoni D et al (2020) Heart failure in the last year: progress and perspective. ESC Heart Failure 7(6):3505\u20133530","journal-title":"ESC Heart Failure"},{"issue":"9\u201310","key":"10397_CR4","doi-asserted-by":"publisher","first-page":"e1932","DOI":"10.7205\/MILMED-D-17-00017","volume":"182","author":"AH Lin","year":"2017","unstructured":"Lin AH et al (2017) Repeat hospitalizations predict mortality in patients with heart failure. Mil Med 182(9\u201310):e1932\u2013e1937","journal-title":"Mil Med"},{"issue":"20","key":"10397_CR5","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","volume":"382","author":"PW Armstrong","year":"2020","unstructured":"Armstrong PW et al (2020) Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 382(20):1883\u20131893","journal-title":"N Engl J Med"},{"key":"10397_CR6","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1007\/s12325-020-01456-1","volume":"37","author":"J Butler","year":"2020","unstructured":"Butler J et al (2020) Clinical and economic burden of chronic heart failure and reduced ejection fraction following a worsening heart failure event. Adv Ther 37:4015\u20134032","journal-title":"Adv Ther"},{"key":"10397_CR7","doi-asserted-by":"publisher","unstructured":"Bui A, Horwich T, Fonarow G (2011) Epidemiology and risk profile of heart failure. Nature Rev Cardiol 8(1):30\u201341. Epub 2010\/11\/10.\u00a0https:\/\/doi.org\/10.1038\/nrcardio.2010.165. PMID: 21060326","DOI":"10.1038\/nrcardio.2010.165"},{"issue":"1","key":"10397_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12872-018-0815-3","volume":"18","author":"W Lesyuk","year":"2018","unstructured":"Lesyuk W, Kriza C, Kolominsky-Rabas P (2018) Cost-of-illness studies in heart failure: a systematic review 2004\u20132016. BMC Cardiovasc Disord 18(1):1\u201311","journal-title":"BMC Cardiovasc Disord"},{"key":"10397_CR9","doi-asserted-by":"crossref","unstructured":"Tumanan-Mendoza BA et al (2018) Economic burden of hospitalisation for congestive heart failure among adults in the Philippines. Heart Asia 10(2)","DOI":"10.1136\/heartasia-2018-011039"},{"key":"10397_CR10","doi-asserted-by":"crossref","unstructured":"Kristin E et al (2022) Budget impact analysis of Sacubitril Valsartan in the Treatment of heart failure and reduced ejection fraction (HFrEF) in Indonesia setting. Indo J Pharm 83\u201392","DOI":"10.22146\/ijp.2529"},{"key":"10397_CR11","doi-asserted-by":"crossref","unstructured":"Zhang Y et al (2023) Current status and challenges in prenatal and neonatal screening, diagnosis, and management of congenital heart disease in China. The Lancet Child Adolesc Health","DOI":"10.1016\/S2352-4642(23)00051-2"},{"issue":"9","key":"10397_CR12","doi-asserted-by":"publisher","first-page":"A607","DOI":"10.1016\/j.jval.2017.08.1185","volume":"20","author":"C Cariou","year":"2017","unstructured":"Cariou C et al (2017) Budget impact analysis of sacubitril\/valsartan introduction for heart failure treatment from the French hospital perspective. Value in Health 20(9):A607","journal-title":"Value in Health"},{"issue":"10","key":"10397_CR13","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.5603\/KP.2016.0141","volume":"74","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Kardiologia Polska (Polish Heart Journal) 74(10):1037\u20131147","journal-title":"Kardiologia Polska (Polish Heart Journal)"},{"issue":"1","key":"10397_CR14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41371-020-00393-4","volume":"35","author":"A Piperidou","year":"2021","unstructured":"Piperidou A, Loutradis C, Sarafidis P (2021) SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives. J Hum Hypertens 35(1):12\u201325","journal-title":"J Hum Hypertens"},{"issue":"5","key":"10397_CR15","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.21037\/jtd-22-463","volume":"14","author":"X Lin","year":"2022","unstructured":"Lin X et al (2022) Cost-effectiveness of empagliflozin as a treatment for heart failure with reduced ejection fraction: an analysis from the Chinese healthcare perspective. J Thorac Dis 14(5):1588","journal-title":"J Thorac Dis"},{"issue":"5","key":"10397_CR16","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1634\/theoncologist.2015-0498","volume":"21","author":"J Sul","year":"2016","unstructured":"Sul J et al (2016) FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1. Oncologist 21(5):643\u2013650","journal-title":"Oncologist"},{"key":"10397_CR17","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2165\/00019053-200119060-00001","volume":"19","author":"P Trueman","year":"2001","unstructured":"Trueman P, Drummond M, Hutton J (2001) Developing guidance for budget impact analysis. Pharmacoeconomics 19:609\u2013621","journal-title":"Pharmacoeconomics"},{"key":"10397_CR18","doi-asserted-by":"crossref","unstructured":"Mauskopf J et al (2017) Introduction to budget-impact analysis. Budget-Impact Analysis of Health Care Interventions: A Practical Guide 1\u201310","DOI":"10.1007\/978-3-319-50482-7_1"},{"issue":"6","key":"10397_CR19","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s10198-011-0348-5","volume":"12","author":"L Garattini","year":"2011","unstructured":"Garattini L, van de Vooren K (2011) Budget impact analysis in economic evaluation: a proposal for a clearer definition. Eur J Health Econ 12(6):499\u2013502","journal-title":"Eur J Health Econ"},{"issue":"1","key":"10397_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","volume":"17","author":"SD Sullivan","year":"2014","unstructured":"Sullivan SD et al (2014) Budget impact analysis\u2014principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value in health 17(1):5\u201314","journal-title":"Value in health"},{"key":"10397_CR21","doi-asserted-by":"publisher","first-page":"421","DOI":"10.5123\/S1679-49742017000200020","volume":"26","author":"MT Silva","year":"2017","unstructured":"Silva MT, Silva END, Pereira MG (2017) Budget impact analysis. Epidemiologia e Servi\u00e7os de Sa\u00fade 26:421\u2013424","journal-title":"Epidemiologia e Servi\u00e7os de Sa\u00fade"},{"issue":"5","key":"10397_CR22","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1524-4733.2007.00187.x","volume":"10","author":"JA Mauskopf","year":"2007","unstructured":"Mauskopf JA et al (2007) Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices\u2014budget impact analysis. Value in health 10(5):336\u2013347","journal-title":"Value in health"},{"key":"10397_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg 88:105906","journal-title":"Int J Surg"},{"key":"10397_CR24","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1007\/s12325-021-01681-2","volume":"38","author":"A Alsumali","year":"2021","unstructured":"Alsumali A et al (2021) Budget impact analysis of vericiguat for the treatment of chronic heart failure with reduced ejection fraction following a worsening event. Adv Ther 38:2631\u20132643","journal-title":"Adv Ther"},{"key":"10397_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12872-021-01958-y","volume":"21","author":"J Bisognano","year":"2021","unstructured":"Bisognano J et al (2021) Cost-impact analysis of baroreflex activation therapy in chronic heart failure patients in the United States. BMC Cardiovasc Disord 21:1\u20139","journal-title":"BMC Cardiovasc Disord"},{"issue":"11","key":"10397_CR26","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1001\/jamacardio.2020.2822","volume":"5","author":"TA Gaziano","year":"2020","unstructured":"Gaziano TA et al (2020) Cost-effectiveness of sacubitril-valsartan in hospitalized patients who have heart failure with reduced ejection fraction. JAMA cardiology 5(11):1236\u20131244","journal-title":"JAMA cardiology"},{"issue":"9","key":"10397_CR27","first-page":"1064","volume":"22","author":"JS Borer","year":"2016","unstructured":"Borer JS et al (2016) Budget impact of adding ivabradine to standard of care in patients with chronic systolic heart failure in the United States. J Manag Care Spec Pharm 22(9):1064\u20131071","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"10397_CR28","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.clinthera.2005.06.014","volume":"27","author":"DG Smith","year":"2005","unstructured":"Smith DG, Cerulli A, Frech FH (2005) Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis. Clin Ther 27(6):951\u2013959","journal-title":"Clin Ther"},{"issue":"3","key":"10397_CR29","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3111\/13696990701438645","volume":"10","author":"DG Smith","year":"2007","unstructured":"Smith DG et al (2007) Estimated cost savings associated with the use of valsartan in heart failure in a large US health plan. J Med Econ 10(3):229\u2013238","journal-title":"J Med Econ"},{"issue":"2","key":"10397_CR30","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3111\/13696998.2011.643329","volume":"15","author":"JR Chiong","year":"2012","unstructured":"Chiong JR et al (2012) Evaluation of costs associated with tolvaptan-mediated length-of-stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial. J Med Econ 15(2):276\u2013284","journal-title":"J Med Econ"},{"issue":"3","key":"10397_CR31","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/ejhf.2788","volume":"25","author":"P McEwan","year":"2023","unstructured":"McEwan P et al (2023) Impact of ferric carboxymaltose for iron deficiency at discharge after heart failure hospitalization: a European multinational economic evaluation. Eur J Heart Fail 25(3):389\u2013398","journal-title":"Eur J Heart Fail"},{"key":"10397_CR32","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s40273-018-0688-4","volume":"36","author":"A Gandjour","year":"2018","unstructured":"Gandjour A, Ostwald DA (2018) Sacubitril\/valsartan (LCZ696): a novel treatment for heart failure and its estimated cost effectiveness, budget impact, and disease burden reduction in Germany. Pharmacoeconomics 36:1285\u20131296","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10397_CR33","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/ehf2.12179","volume":"4","author":"U Theidel","year":"2017","unstructured":"Theidel U et al (2017) Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany. ESC heart failure 4(3):274\u2013281","journal-title":"ESC heart failure"},{"issue":"3","key":"10397_CR34","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/ehf2.12432","volume":"6","author":"S Bourguignon","year":"2019","unstructured":"Bourguignon S et al (2019) Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France. ESC heart failure 6(3):559\u2013569","journal-title":"ESC heart failure"},{"issue":"12","key":"10397_CR35","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1080\/13696998.2020.1838872","volume":"23","author":"JF Delgado","year":"2020","unstructured":"Delgado JF et al (2020) Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain. J Med Econ 23(12):1418\u20131424","journal-title":"J Med Econ"},{"key":"10397_CR36","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.vhri.2023.02.009","volume":"36","author":"RN Leong","year":"2023","unstructured":"Leong RN et al (2023) Budget impact analysis of utilization of Sacubitril\/Valsartan for the treatment of heart failure with reduced ejection fraction in the Philippines. Value in Health Regional Issues 36:105\u2013116","journal-title":"Value in Health Regional Issues"},{"issue":"1","key":"10397_CR37","doi-asserted-by":"publisher","first-page":"S107","DOI":"10.1016\/j.jval.2021.11.511","volume":"25","author":"K Ratanasumawong","year":"2022","unstructured":"Ratanasumawong K, Piyayotai D, Makarawate P (2022) POSC106 budget impact analysis of including Sacubitril\/Valsartan in the national formulary for the treatment of Heart Failure with Reduced Ejection Fraction (HFREF) in Thailand. Value in Health 25(1):S107","journal-title":"Value in Health"},{"key":"10397_CR38","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s10198-013-0533-9","volume":"15","author":"E Brock","year":"2014","unstructured":"Brock E et al (2014) Budget impact of parenteral iron treatment of iron deficiency: methodological issues raised by using real-life data. Eur J Health Econ 15:907\u2013916","journal-title":"Eur J Health Econ"},{"key":"10397_CR39","unstructured":"Wong B et al (2021) Study of patients with iron deficiency and HF in Ireland: prevalence and treatment budget impact. The British J Cardiol 28(1)"},{"issue":"11","key":"10397_CR40","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.2217\/cer-2019-0074","volume":"8","author":"C Rognoni","year":"2019","unstructured":"Rognoni C, Gerzeli S (2019) Ferric carboxymaltose for patients with heart failure and iron deficiency in Italy: cost\u2013effectiveness and budget impact. Journal of comparative effectiveness research 8(11):1099\u20131110","journal-title":"Journal of comparative effectiveness research"},{"issue":"4","key":"10397_CR41","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2478\/jce-2019-0018","volume":"5","author":"L Lorenzovici","year":"2019","unstructured":"Lorenzovici L et al (2019) Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Romania. Journal of Cardiovascular Emergencies 5(4):131\u2013139","journal-title":"Journal of Cardiovascular Emergencies"},{"issue":"1","key":"10397_CR42","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1017\/S0266462309090072","volume":"25","author":"MG Niezen","year":"2009","unstructured":"Niezen MG et al (2009) Finding legitimacy for the role of budget impact in drug reimbursement decisions. Int J Technol Assess Health Care 25(1):49\u201355","journal-title":"Int J Technol Assess Health Care"},{"issue":"3","key":"10397_CR43","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jval.2017.12.017","volume":"21","author":"SD Pearson","year":"2018","unstructured":"Pearson SD (2018) The ICER value framework: integrating cost effectiveness and affordability in the assessment of health care value. Value in health 21(3):258\u2013265","journal-title":"Value in health"},{"issue":"4","key":"10397_CR44","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.hrtlng.2017.04.001","volume":"46","author":"N McCabe","year":"2017","unstructured":"McCabe N et al (2017) Six-minute walk distance predicts 30-day readmission after acute heart failure hospitalization. Heart Lung 46(4):287\u2013292","journal-title":"Heart Lung"},{"key":"10397_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12872-018-0898-x","volume":"18","author":"O Borisenko","year":"2018","unstructured":"Borisenko O et al (2018) An early analysis of cost-utility of baroreflex activation therapy in advanced chronic heart failure in Germany. BMC Cardiovasc Disord 18:1\u201310","journal-title":"BMC Cardiovasc Disord"},{"issue":"3","key":"10397_CR46","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.jjcc.2021.10.026","volume":"79","author":"Y Nakao","year":"2022","unstructured":"Nakao Y et al (2022) Cost-effectiveness of long-term tolvaptan administration for chronic heart failure treatment in Japan. J Cardiol 79(3):408\u2013416","journal-title":"J Cardiol"},{"issue":"4","key":"10397_CR47","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/21548331.2018.1505180","volume":"46","author":"JF Dasta","year":"2018","unstructured":"Dasta JF et al (2018) Economic impact of tolvaptan treatment vs. fluid restriction based on real-world data among hospitalized patients with heart failure and hyponatremia. Hosp Pract 46(4):197\u2013202","journal-title":"Hosp Pract"},{"issue":"9744","key":"10397_CR48","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","volume":"376","author":"K Swedberg","year":"2010","unstructured":"Swedberg K et al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. The Lancet 376(9744):875\u2013885","journal-title":"The Lancet"},{"issue":"5","key":"10397_CR49","doi-asserted-by":"publisher","first-page":"407","DOI":"10.7861\/clinmedicine.16-5-407","volume":"16","author":"K Guha","year":"2016","unstructured":"Guha K et al (2016) Audit of a tertiary heart failure outpatient service to assess compliance with NICE guidelines. Clin Med 16(5):407","journal-title":"Clin Med"},{"key":"10397_CR50","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.vhri.2020.04.003","volume":"23","author":"J-D Rueda","year":"2020","unstructured":"Rueda J-D et al (2020) Limitations and challenges of conducting budget impact analyses in rare diseases: a case study of alpha-1 antitrypsin deficiency. Value in Health Regional Issues 23:70\u201376","journal-title":"Value in Health Regional Issues"},{"issue":"1","key":"10397_CR51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12962-019-0198-z","volume":"18","author":"L Han","year":"2020","unstructured":"Han L et al (2020) A systematic review of the budget impact analyses for antitumor drugs of lung cancer. Cost Effect Resour A 18(1):1\u201310","journal-title":"Cost Effect Resour A"}],"updated-by":[{"DOI":"10.1007\/s10741-024-10400-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T00:00:00Z","timestamp":1711324800000}}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-024-10397-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-024-10397-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-024-10397-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T12:08:09Z","timestamp":1731586089000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-024-10397-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,16]]},"references-count":51,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["10397"],"URL":"https:\/\/doi.org\/10.1007\/s10741-024-10397-8","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10741-024-10400-2","asserted-by":"object"}]},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,16]]},"assertion":[{"value":"7 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10741-024-10400-2","URL":"https:\/\/doi.org\/10.1007\/s10741-024-10400-2","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study does not require official ethical endorsement because it will not include the gathering of primary data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}